Napa One Tablet 1000 mg

Napa One Tablet is a trusted analgesic containing Paracetamol 1000 mg manufactured by Beximco Pharmaceuticals Ltd. Designed for rapid pain relief, it effectively treats fever, headaches, dental pain, and post-vaccination discomfort in children. This tablet form ensures convenient dosing for adults and children above 12 years.

Priced at ৳2.25 per unit, Napa One offers cost-effective therapy with a strip price of ৳22.50. The 20×10 pack (৳450.00) suits long-term needs. Its non-opioid formula makes it safer than NSAIDs for gastric-sensitive patients, though alcohol consumption during treatment may increase liver risks.

Pharmacologically, Paracetamol inhibits CNS prostaglandin synthesis through COX enzyme modulation. Unlike other analgesics, it lacks significant anti-inflammatory effects but provides swift fever reduction. Clinical studies confirm its efficacy in menstrual pain, osteoarthritis, and post-surgical recovery.

Dosage Guidelines:

• Adults: 1-2 tablets every 4-6 hours (max 8 tablets/day)
• Children (6-12 years): ½-1 tablet 3-4 times daily

Notable drug interactions include barbiturates, alcohol, and anticonvulsants which may reduce efficacy. Mild side effects like skin rashes occur rarely. Pregnant/lactating women should consult doctors despite its established safety profile. Overdoses exceeding 10g require immediate NAC therapy to prevent hepatic failure.

Adults: 1-2 tablets every 4-6 hours (max 8 tablets/day). Children (6-12 years): 0.5-1 tablet 3-4 times daily. Renal patients require extended dosing intervals. Can be taken with/without food. Do not exceed 3-5 days without medical supervision.

Side effects of Napa One are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.

Pregnancy Category B. Short-term use under medical supervision considered safe. Excreted minimally in breast milk – compatible with lactation.

Monitor LFT and renal function in hepatic/renal impairment patients. Periodic CBC required during prolonged use. Avoid concurrent alcohol. Do not combine with other paracetamol-containing tablets.

Pediatrics: Contraindicated <3 months. Geriatrics: Dose adjustment may needed. Hepatic: Max 2g/day. Renal: 8-hour interval if CrCl <30 ml/min.

Liver damage is possible in adults who have taken 10 g or more of Napa One. Ingestion of 5 g or more of Napa One may lead to liver damage if the patient has following risk factors: If the patient is on long term treatment with Carbamazepine, Phenobarbitone, Phenytoin, Primidone, Rifampicin, St John’s Wort or other drugs that induce liver enzymes, or regularly consumes Ethanol in excess of recommended amounts, or is likely to be Glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms: Symptoms of Napa One overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Immediate treatment is essential in the management of Napa One overdose. Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Napa One concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Napa One. However, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral Methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.